NCT06649877View on ClinicalTrials.gov

MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

July 13, 2023

Study Completion Date

July 13, 2023

Conditions

Healthy

Interventions

BIOLOGICAL

MK-6194

single injected dose

Trial Locations (1)

33143

QPS-MRA, LLC-Early Phase (Site 0001), South Miami

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY